IMVT
Immunovant, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.62
+3.33%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.74
- Revenue estimate
- $7.1M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.75
- EPS estimate
- -$0.63
- Revenue actual
- $7.1M
- Revenue estimate
- $7.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 9
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -3.8%
- Revenue beats (12Q)
- 0
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.63 | -$0.75 | Miss -19.26% | $7.1M |
| May 20, 2026 | -$0.60 | -$0.73 | Miss -21.67% | — |
| Feb 6, 2026 | -$0.72 | -$0.61 | Beat 15.35% | — |
| May 29, 2025 | -$0.71 | -$0.64 | Beat 10.27% | — |
| Feb 6, 2025 | -$0.73 | -$0.76 | Miss -4.11% | — |
| Nov 7, 2024 | -$0.60 | -$0.74 | Miss -23.33% | — |
| May 29, 2024 | -$0.43 | -$0.52 | Miss -20.93% | — |
| Nov 9, 2023 | -$0.47 | -$0.45 | Beat 4.26% | — |
| Aug 10, 2023 | -$0.45 | -$0.57 | Miss -26.67% | — |
| May 22, 2023 | -$0.43 | -$0.46 | Miss -6.98% | — |
| Feb 3, 2023 | -$0.39 | -$0.49 | Miss -25.64% | — |
| Nov 4, 2022 | -$0.39 | -$0.41 | Miss -5.13% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026